Analysts have clear opinions on DXCM.

There are 13 analysts on the Wall offering 12 month price targets for Dexcom in the last 3 months. The average price target is $225.90 with a high forecast of $255.00 and a low forecast of $189.00. The average price target represents a -3.60% decrease from the last price of $234.34.
DexCom, Inc. (DXCM) is followed by 13 analysts on the street.

Matthew O’Brien from Piper Sandler rates it a Buy.

Similarly, 8 days ago Doug Schenkel of Cowen & Co. Reiterated a Buy with a target of $250.00.

The consensus on the street is Strong Buy.

What does DexCom, Inc.(DXCM) do ?
DexCom, Inc. is a medical device manufacturing company, which engages in the design, development, and commercialization of continuous glucose monitoring systems for ambulatory use by people with diabetes. Its products include Dexcom G4 PLATINUM System, DexCom G5 Mobil, DexCom Share,and Mobile apps. The company was founded by John F. Burd in May 1999 and is headquartered in San Diego, CA.

DexCom, Inc. (DXCM) Insider Trades

Multiple company employees have indulged in significant insider trading. DexCom, Inc. disclosed the following in a document filed with the US Securities and Exchange Commission (SEC):

Pres, CEO, COB, Sayer Kevin R : S – Dirty(- $ 1,383,710) of DXCM in the trading session of 2020-01-13.

SVP, Legal Affairs Murphy Patrick Michael : S – Dirty(- $ 117.505) of DXCM in the trading session of 2020-01-09.

dir Skyler Jay S : S – Dirty(- $ 5,621,816) of DexCom, Inc. in the trading session of 2020-01-03.

Looking for stocks just like DXCM?

Based on Wall Street analyst research, several stocks are similar to DXCM
They are:
– JNJ [Info can be found here: ]
– SENS [Info can be found here: ]
– RHHBY [Info can be found here: ]